Geron(GERN) Prnewswire·2025-03-21 09:45Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud that affected investors between June 7, 2024, and February 25, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Geron misled investors regarding the launch and growth potential of its drug Rytelo (imetelstat), downplaying risks associated with monitoring requirements and competition [2] - Following the announcement of Geron's fourth quarter financial results for fiscal 2024 on February 26, 2025, which revealed that Rytelo's growth had flattened, the company's stock price dropped significantly from 1.61 per share, a decline of approximately 32.07% in one day [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until May 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4]